Promising Targets for Bladder Cancer
Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.
Joshua J. Meeks, MD, Edward M. Schaeffer, MD, PhD Professor of Urology, and associate professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, discusses investigational targets in the bladder cancer space.
One of the most promising targeted in bladder cancer to date is FGFR3, according to Meek. In patients with advanced disease or muscle invasive disease, FGFR3 alterations exists but are less frequent compared with early-stage disease. Meeks said the 40% or more patients with early-stage bladder cancer have FGFR3 alterations.
The unanswered questions physicians have is how to target FGFR3, weigh the benefits, and limit treatment toxicity, explained Meeks.
Investigational FGFR3-Selective Inhibitor Shows Promise in Urothelial Cancer
October 28th 2024TYRA-300 showed promising safety and preliminary antitumor activity in FGFR3-altered metastatic urothelial cancer, with a 54.5% partial response rate and 100% disease control in the SURF301 trial.
Read More
